Mesenchymal Stem Cell Therapy for ALI/ARDS : Therapeutic Potential and Challenges
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a serious clinical common disease caused by various pathological factors and can induce serious complications. There is still no specific and effective method for the treatment of ALI/ARDS. Mesenchymal stem cells (MSCs) have been one of the treatment methods for ALI, which can regulate related signal pathways such as PI3K/AKT, Wnt, and NF-κB to reduce inflammation. MSCs exist in various tissues and can self-renewal and differentiation, which can be activated by specific substances or environments and home to the site of tissue damage, where they differentiate into new tissue cells and repair the damage. Both exosomes and cytokines involving the paracrine mechanism of MSCs have benefits in treating ALI. Lung organoids produced by 3D culture technology can simulate the lung's characteristics and help research the pathophysiological process of ALI. This review summarizes the mechanisms by which MSCs treat ALI/ARDS and expects to use 3D models for future challenges in this field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 28(2022), 27 vom: 07., Seite 2234-2240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Zhenxing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lung injury |
|---|
| Anmerkungen: |
Date Completed 16.09.2022 Date Revised 27.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612828666220707104356 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343170450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343170450 | ||
| 003 | DE-627 | ||
| 005 | 20231226015813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612828666220707104356 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343170450 | ||
| 035 | |a (NLM)35796453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Zhenxing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesenchymal Stem Cell Therapy for ALI/ARDS |b Therapeutic Potential and Challenges |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2022 | ||
| 500 | |a Date Revised 27.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a serious clinical common disease caused by various pathological factors and can induce serious complications. There is still no specific and effective method for the treatment of ALI/ARDS. Mesenchymal stem cells (MSCs) have been one of the treatment methods for ALI, which can regulate related signal pathways such as PI3K/AKT, Wnt, and NF-κB to reduce inflammation. MSCs exist in various tissues and can self-renewal and differentiation, which can be activated by specific substances or environments and home to the site of tissue damage, where they differentiate into new tissue cells and repair the damage. Both exosomes and cytokines involving the paracrine mechanism of MSCs have benefits in treating ALI. Lung organoids produced by 3D culture technology can simulate the lung's characteristics and help research the pathophysiological process of ALI. This review summarizes the mechanisms by which MSCs treat ALI/ARDS and expects to use 3D models for future challenges in this field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Mesenchymal stem cells | |
| 650 | 4 | |a PI3K/AKT | |
| 650 | 4 | |a acute lung injury | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 650 | 4 | |a hypoxemia | |
| 650 | 4 | |a lung organoid | |
| 700 | 1 | |a Yu, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yapeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Hongguang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 28(2022), 27 vom: 07., Seite 2234-2240 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:27 |g day:07 |g pages:2234-2240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612828666220707104356 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 27 |b 07 |h 2234-2240 | ||